eMultipleSclerosis Review

Too many individuals with MS are not receiving access to the most effective care. Why? What’s behind these disparities? And what can individual clinicians do to help remove the barriers that prevent equitable care for all patients?Join us, as Dr. Dorlan Kimbrough, from the division of Neurology, Multiple Sclerosis, and Neuroimmunology at the Duke University School of Medicine, discusses these topics, in this issue of eMultipleSclerosis Review. 

Take our post-test to claim CME credits.

Read this podcast's companion newsletter here.

Hosted on Acast. See acast.com/privacy for more information.

How burdensome is spasticity for patients with MS? What’s the approach to treatment, and how effective is it? What do patients and clinicians need to know about cannabis-based therapies?  

These are the key questions Program Director Dr. Michael Kornberg from the Johns Hopkins School of Medicine discusses with guest MS spasticity experts in this second part of this eMultipleSclerosis Review Special Edition. 

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

In her Expert Commentary, Dr. Melanie Ward from West Virginia University’s Rockefeller Neuroscience Institute provided analysis of the newer data describing the modifiable and nonmodifiable risk factors for developing MS and/or increasing the rate of disease progression and disability.

Join us for this podcast as Dr. Ward explains how these findings can affect clinical practice to improve overall care of individuals with MS. 

Take our post-test to claim CME credits.

Read this podcast's companion newsletter here.

Hosted on Acast. See acast.com/privacy for more information.

How aware are clinicians that MS should no longer be considered a “White people only” disease? What roles have race and ethnicity been shown to play in MS disease severity and disability progression? What do health care professionals need to know to provide the most effective care for all their patients?

Join Dr. Yujie Wang from the University of Washington and Dr. Kimystian Harrison, a post doctoral fellow at Johns Hopkins University, as they explore these and other questions in this eMultipleSclerosis Review podcast.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

Where’s the newer MS research leading? How has our understanding of noninflammatory progressive MS changed? How might these findings affect what happens in the clinic? 

Join us as we discuss these and other questions with Dr. Michael Kornberg from the Johns Hopkins School of Medicine in this eMultipleSclerosis Review podcast. 

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

Is it true that a significant number of patients being treated for MS may not actually have the disease? What are the red flags — warnings that something about the patient’s condition does not meet the accepted MS diagnostic criteria — that need to be investigated?   

Join us in this eMultipleSclerosis Review podcast, as Neuroimmunologist Dr. Gabrielle Macaron from Saint Joseph University’s Hotel Dieu de France Hospital in Beirut, Lebanon, and the Cleveland Clinic’s Mellen Center for Multiple Sclerosis, explains strategies to reduce misdiagnosis of MS. 

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

In this Issue: Fatigue. Urinary dysfunction. Constipation. Spasticity and gait problems. Providing relief from these common MS symptoms often requires clinicians to go beyond the prescription pad to recommend nonpharmacologic treatments. What works? What doesn’t? What does the evidence say? 

Join us as Dr. W. Oliver Tobin from the Mayo Clinic discusses these questions in this eMultipleSclerosis Review podcast.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

As people with MS age, how does their response to their long-term DMT change? Is there a time when disease-modifying therapy can be safely discontinued? In which patients? At what age? What role do comorbidities play in making these decisions?  

Join us as we discuss these questions with Dr. Burcu Zeydan from the Mayo Clinic in this eMultipleSclerosis Review podcast. 

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

COVID-19 vaccination. For many people with multiple sclerosis, it’s not a simple and straightforward process. The DMT they’re currently taking to control disease progression and moderate their symptoms — particularly if it’s a beta cell- depleting agent — may prevent the vaccine from working as it’s supposed to. What do clinicians need to know, and how should they explain it to their patients?  

Dr. Joseph Sabatino from the University of California San Francisco presented the basics in his recent newsletter issue; now he brings that information into the clinic in this eMultipleSclerosis Review podcast. 

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

Shared decision-making — what does it mean in multiple sclerosis? Can it really help providers more fully understand their patients’ concerns? Can it motivate patients to more readily and enthusiastically take ownership of their disease? And most important, how can it be developed in the clinic? 

Join us in this eMultipleSclerosis Review podcast, as we talk about the why and how of shared decision-making in MS with PA Lisa Fox from the Department of Neurology at Johns Hopkins Hospital in Baltimore.  

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.